 The FDA has cleared Adagene Incs NASDAQ: ADAG Investigational New Drug IND application to proceed with a Phase 1b2 trial of ADG116, in combination with Merck Co Inc NYSE: MRK Keytruda pembrolizumab. The global trial ADG116-P001 KEYNOTE-C97 will evaluate patients with advancedmetastatic solid tumors at multiple sites in the U.S. and the Asia Pacific APAC. 